Ultragenyx wins FDA greenlight for first Sanfilippo therapy, priced at nearly $4M

The market approval for Fayuvi, which was rejected in 2025 due to manufacturing problems, comes shortly after Ultragenyx got the FDA nod for its first gene therapy last month.